

RECORD OF TELEPHONE CONVERSATION

Submission Information

Application Type	BLA
STN	125597/0.0
Review Office	OVRR
Applicant	Pax Vax Bermuda Ltd. / Lic. # 2041
Product	Cholera Vaccine Live Oral
Trans-BLA Group:	No

Telecon Details

Telecon Date/Time	10-MAY-2016 01:42 PM
Author	SEN, GOUTAM
EDR	No
Post to Web	No
Outside Phone Number	
FDA Originated?	Yes
Communication Categories	AD - Advice
Related STNs	None
Related PMCs	None
Telecon Summary	Clarification of May 6, 2016, comment#3 sent by email
FDA Participants	Goutam Sen
Applicant Participants	Kevin Smyth

Telecon Body:

From: Kevin Smyth [mailto:KSmyth@paxvax.com]

Sent: Tuesday, May 10, 2016 8:42 AM

To: Sen, Goutam

Subject: RE: Response to your Question and Information request for DP potency, STN: 125597

RECORD OF TELEPHONE CONVERSATION

Dear Goutam,

Thanks for the clarification!

Regards, Kevin

This E-Mail may contain proprietary, confidential or privileged information intended solely for the addressee. If you are not the intended recipient, any use, copying, disclosure, dissemination or distribution is strictly prohibited. If you received this message in error, please notify the sender immediately by return E-Mail, delete this communication and destroy all copies.

From: Sen, Goutam [<mailto:Goutam.Sen@fda.hhs.gov>]

Sent: Tuesday, May 10, 2016 13:16

To: Kevin Smyth

Subject: RE: Response to your Question and Information request for DP potency, STN: 125597

Dear Kevin,

Here is the clarification of our May 6, 2016, information request, item#3 as per your request: "If you currently have data regarding the impact of different sources of bottled water and the impact of different thaw durations on drug product potency, using drug product that was manufactured using the bulk drug substance hold time of (b) (4), please provide it. However, if you do not, we are not requesting that you obtain such additional data at this time."

Please let me know if you have any question.

Thank you,

Goutam

From: Kevin Smyth [<mailto:KSmyth@paxvax.com>]

Sent: Friday, May 06, 2016 4:39 PM

To: Sen, Goutam

Subject: RE: Response to your Question and Information request for DP potency, STN: 125597

Dear Goutam,

Regarding Item 3 – The paragraph states that we have not provided data for the hold time of (b) (4), and then goes on to discuss data required to support post-approval changes. Would you please clarify if you would require that reconstitution data for the hold time of (b) (4) be submitted prior June 15 (i.e. no manufacturing changes).

Regards, Kevin

This E-Mail may contain proprietary, confidential or privileged information intended solely for the addressee. If you are not the intended recipient, any use, copying, disclosure, dissemination or distribution is strictly prohibited. If you received this message in error, please notify the sender immediately by return E-Mail, delete this communication and destroy all copies.

RECORD OF TELEPHONE CONVERSATION

From: Sen, Goutam [<mailto:Goutam.Sen@fda.hhs.gov>]

Sent: Friday, May 06, 2016 11:45

To: Kevin Smyth

Subject: Response to your Question and Information request for DP potency, STN: 125597

Dear Kevin,

Thank you for the telephone conversation of this morning, discussing some of our questions/comment. As we stated during this morning's telecon, I am sending our response to your question as well as information request. Please submit your response as an amendment to your STN: 125597.

- 1) The lower limit of the potency (b) (4) of your DP as stated in 2b of our May 5, 2016 email IR should be stated as: 4×10^8
- 2) We note that your proposed potency acceptance criteria are 4×10^8 to 2×10^9 CFU/dose, with a target sachet fill of (b) (4) CFU/dose. In addition, in your stability data, we note that the potency of lots with initial potency of 1×10^9 CFU/dose decreased to a range of $4-6 \times 10^8$ CFU/dose after 18 months of storage at $-20 \pm 5^\circ\text{C}$. Please comment on how you will ensure and/or monitor whether the potency of the drug product remains within the acceptance criteria through the end of the proposed 18-month dating period, considering that some lots may have initial potency toward the lower end of the range of the acceptance criteria.
- 3) In your correspondence dated April 22, 2016, you stated that the lot used to study the impact of different sources of bottled water and the impact of different thaw durations on drug product potency (Figures 1 and 5 of the compatibility document in module 3.2.P.2.6 of STN 125597_0) was manufactured using bulk drug substance that was stabilized using a (b) (4) hold time, a manufacturing process that you have withdrawn from your BLA. You have not provided corresponding data using drug product manufactured using a bulk drug substance hold time of (b) (4), which is the manufacturing process that you are proposing in your BLA. If you intend to propose a change in the manufacturing process in the future, at that time, please include results of a study of the impact on potency of different sources of bottled water, different lengths of sachet thaw time, and different hold times after reconstitution. Please include Water for Irrigation, USP, as one of the bottled water types assessed. Please conduct the study using drug product manufactured using the process proposed in your BLA and drug product manufactured using the proposed change, for comparison purposes. In addition, please include tests of a worst-case scenario, in which the type of bottled water that yields the lowest potency result is assessed in studies of sachet thaw time and reconstituted vaccine hold time.

RECORD OF TELEPHONE CONVERSATION

Please let me know if you have any question.

Thank you,

Goutam

From: Kevin Smyth [<mailto:KSmyth@paxvax.com>]

Sent: Friday, May 06, 2016 2:32 AM

To: Sen, Goutam

Subject: RE: CBER comments to Vaxchora Package insert and carton labels, STN: 125597

Dear Goutam,

We have begun our internal meetings to review and align on FDA's recommended label revisions, and I commit to a full response by no later than March 19.

We note that the potency range lower limit has been (b) (4) from 4x10E8 to (b) (4), and have a couple of follow-up requests/clarifications:

- Would you please provide brief justification for the (b) (4), in light of the fact that P3 subjects were administered product at 4.2x10E8?
- At this time may I ask you to please reiterate your intent to grant at least 18M of drug product shelf-life for a lower potency limit of (b) (4)
- No request was received to change the drug product release specification from 4x10E8 to (b) (4) ...might additional specification-related changes be forthcoming?

Thanks so much for any response you can provide to the above.

Regards, Kevin

This E-Mail may contain proprietary, confidential or privileged information intended solely for the addressee. If you are not the intended recipient, any use, copying, disclosure, dissemination or distribution is strictly prohibited. If you received this message in error, please notify the sender immediately by return E-Mail, delete this communication and destroy all copies.

From: Sen, Goutam [<mailto:Goutam.Sen@fda.hhs.gov>]

Sent: Thursday, May 05, 2016 12:43

To: Kevin Smyth

Subject: CBER comments to Vaxchora Package insert and carton labels, STN: 125597

Dear Kevin,

Please find the attached word document containing our edit/comment to your Vaxchora package insert. Also, please find below our comments to your Buffer and Vaccine sachet carton label. Please submit your response to these comments as an amendment to your STN by May 19, 2016. Please let me know if you have any question.

Thank you,

RECORD OF TELEPHONE CONVERSATION

Goutam Sen, Ph.D.
Scientific Reviewer
Food and Drug Administration
Center for Biologics Evaluation and Research
White Oak Bldg. 71
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Telephone: 301-796-2640
Fax: 301-595-1125

CBER Comments Regarding Draft Buffer & Vaccine Sachet Mock-up and Draft Carton Mock-up:

1. Please revise the draft Buffer Sachet as follows:
 - a. Please revise the “BUFFER” label of this sachet to read “BUFFER COMPONENT of VAXCHORA (Cholera Vaccine, Live, Oral).”
 - b. Please add language that emphasizes the importance of using the recommended purified bottled water for reconstitution.
2. Please revise the draft Vaccine Sachet as follows :
 - a. Please revise the “VACCINE” label of this sachet to read “BACTERIAL COMPONENT of VAXCHORA (Cholera Vaccine, Live, Oral).”
 - b. Please revise the contents to read as follows: “Contents (Single-Dose): (b) (4) to 2×10^9 CFU of lyophilized *V. cholerae* CVD 103-HgR.”
 - c. Please delete “Cholera Vaccine, Live, Oral VaxchoraTM,” which is located above the contents, as Vaxchora is the final product after reconstitution of both sachets.
3. The following comments apply generally to both sachets, to reduce the risk of either sachet alone being mistaken for the complete vaccine:
 - a. Please consider redesigning the sachets such that they can accommodate larger labels (to reduce label crowding) and increased font size of important text.
 - b. We recommend that you provide on each sachet clear directions for reconstituting the product and warnings to administer the contents of both sachets.

RECORD OF TELEPHONE CONVERSATION

- c. Please consider labeling each sachet as “Sachet 1 of 2” and “Sachet 2 of 2,” or use a similar scheme to distinguish, yet link, the two sachets, the contents of which must be administered together.
4. Please consider conducting usability testing with vaccine users to test labels, packages and preparation processes for safety, clarity and effectiveness.
5. FDA recommends use of 12-point font wherever label size permits.
6. The following comments apply to the Draft Carton Mock-up:
 - a. We recommend revision of the contents to read as follows: “Contents: Single-dose Bacterial Sachet (b) (4) to 2×10^9 CFU of *V. cholerae* CVD 103-HgR) and Single-dose Buffer Sachet.”
 - b. We recommend revision of the carton to indicate that the vaccine must be reconstituted prior to use.
 - c. We recommend that clear directions for reconstituting the product and warnings to administer the contents of both sachets be included on the front of the carton.

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.

This E-Mail may contain proprietary, confidential or privileged information intended solely for the addressee. If you are not the intended recipient, any use, copying, disclosure, dissemination or distribution is strictly prohibited. If you received this message in error, please notify the sender immediately by return E-Mail, delete this communication and destroy all copies.

This E-Mail may contain proprietary, confidential or privileged information intended solely for the addressee. If you are not the intended recipient, any use, copying, disclosure, dissemination or distribution is strictly prohibited. If you received this message in error, please notify the sender immediately by return E-Mail, delete this communication and destroy all copies.

This E-Mail may contain proprietary, confidential or privileged information intended solely for the addressee. If you are not the intended recipient, any use, copying, disclosure, dissemination or distribution is strictly prohibited. If you received this message in error, please notify the sender immediately by return E-Mail, delete this communication and destroy all copies.